Irish-British scientist Sir Adrian Hill wins European Inventor Award 2026 for highly effective malaria vaccine
- Sir Adrian Hill receives the European Inventor Award 2026 in the Research category for developing the R21/Matrix-M malaria vaccine
- The vaccine achieved around 75–80% protection in clinical trials, exceeding the World Health Organization's target for malaria vaccines
- The invention is designed for large-scale deployment in low-income countries and was recommended by the WHO for widespread use in 2023
- The award was presented during the European Inventor Award 2026 ceremony in Berlin today
Munich, 2 July 2026 – Today, the European Patent Office (EPO) has awarded Irish-British scientist Sir Adrian Hill the European Inventor Award 2026 in the Research category for developing the R21/Matrix-M malaria vaccine. According to the World Health Organization, there were an estimated 282 million malaria cases and 610 000 malaria deaths worldwide in 2024, with children under five accounting for about 75% of malaria deaths in the WHO African Region. Traditional malaria vaccines achieved only modest protection, particularly in young children. Hill and his team developed a vaccine that presents more of the malaria-specific protein regions needed to trigger a strong immune response, helping to achieve around 75–80% protection in clinical trials.
The European Inventor Award recognises inventors whose innovations provide answers to some of the world’s most pressing challenges. The other finalists in the Research category were Portuguese researcher Paula Videira and team for an antibody that distinguishes cancer cells from healthy tissue and Finnish physicist Mikko Möttönen for an ultrasensitive cryogenic microwave sensor to improve quantum computing hardware.
“I am delighted to accept this prestigious award on behalf of the many hundreds of people who have contributed to the discovery, development and licensure of our malaria vaccine over the past 12 years,” said Sir Hill.
Improving protection against malaria
Scientists have been attempting to develop a malaria vaccine for more than a century, yet more than 150 vaccine candidates entered human trials before two finally succeeded. Earlier vaccines, including RTS,S, typically achieved only modest efficacy in young children.
Hill's team redesigned the vaccine structure to include more of the key malaria protein segments recognised by the immune system, while removing components that could divert the immune response. The vaccine forms nanoparticles approximately 25 nanometres in size, helping the immune system recognise and respond more effectively. Combined with the Matrix-M adjuvant, the vaccine generates a substantially stronger antibody response than earlier approaches.
The vaccine was also designed for practical deployment. It can be produced at large scale, costs less than EUR 3 per dose and remains stable for up to two years under standard refrigeration conditions, helping make vaccination programmes more accessible in regions where malaria remains endemic.
Building a vaccine for large-scale deployment
Hill's long-term commitment to malaria research was shaped by his 1988 experience in The Gambia, where he witnessed the devastating impact of the disease on young children. Over the following three decades, his team at Oxford's Jenner Institute investigated multiple vaccine candidates before developing R21/Matrix-M.
The project brought together partners including the University of Oxford, the Serum Institute of India, Novavax and leading African research centres in Burkina Faso, Kenya, Mali and Tanzania. A key milestone came in 2021, when Phase 2b trial results showed up to 77% efficacy, exceeding the WHO target of 75% for malaria vaccines.
Ghana became the first country to approve the vaccine in 2023, followed by Nigeria. Later that year, the WHO formally recommended R21/Matrix-M for widespread use. Today, malaria vaccination is being integrated into routine immunisation programmes in more than 20 African countries, providing a new tool to reduce malaria-related illness and deaths.
All the winners of the 2026 edition of the European Inventor Award were announced at a ceremony today in Berlin. You can stream the ceremony online here. Find more information about the invention’s impact, the technology and the inventor’s stories here.
Media contacts European Patent Office
Roberta Romano-Götsch
EPO spokesperson
EPO press desk
[email protected]
Tel.: +49 89 2399-1833
About the European Inventor Award
The European Inventor Award is one of Europe's most prestigious innovation prizes. Launched by the EPO in 2006, the award honours individuals and teams, who have come up with solutions to some of the biggest challenges of our time. The European Inventor Award jury consists of inventors who are all former finalists. To judge proposals, the independent panel draws on their wealth of technical, business, and intellectual property expertise. All inventors must have been granted a European patent for their invention. Read more here on the various categories, prizes, selection criteria and livestream ceremony held on 2 July in Berlin.
About the EPO
With 6,300 staff members, the European Patent Office (EPO) is one of the largest public service institutions in Europe. Headquartered in Munich with offices in Berlin, Brussels, The Hague and Vienna, the EPO was founded with the aim of strengthening co-operation on patents in Europe. Through the EPO's centralised patent granting procedure, inventors are able to obtain high-quality patent protection in up to 46 countries, covering a market of some 715 million people. The EPO is also the world's leading authority in patent information and patent searching.